CERS3

Across TCGA pan-cancer cohorts, CERS3 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CERS3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CERS3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CERS3 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LSCC and HNSC are the cancer types where CERS3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CERS3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+1.449	<.001	9	view →
HNSC	Male	IV	−0.855	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

CERS3–LSCC

Open the LSCC breakdown →